Summit Therapeutics Statistics
Total Valuation
SMMT has a market cap or net worth of $9.25 billion. The enterprise value is $8.64 billion.
| Market Cap | 9.25B |
| Enterprise Value | 8.64B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SMMT has 799.76 million shares outstanding. The number of shares has increased by 5.30% in one year.
| Current Share Class | 799.76M |
| Shares Outstanding | 799.76M |
| Shares Change (YoY) | +5.30% |
| Shares Change (QoQ) | +2.57% |
| Owned by Insiders (%) | 76.69% |
| Owned by Institutions (%) | 17.14% |
| Float | 154.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 376.90 |
| PB Ratio | 20.04 |
| P/TBV Ratio | 16.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.99, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.99 |
| Quick Ratio | 5.71 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -220.01% and return on invested capital (ROIC) is -136.65%.
| Return on Equity (ROE) | -220.01% |
| Return on Assets (ROA) | -111.99% |
| Return on Invested Capital (ROIC) | -136.65% |
| Return on Capital Employed (ROCE) | -146.79% |
| Weighted Average Cost of Capital (WACC) | -4.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.14M |
| Employee Count | 265 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.03% in the last 52 weeks. The beta is -1.52, so SMMT's price volatility has been lower than the market average.
| Beta (5Y) | -1.52 |
| 52-Week Price Change | -34.03% |
| 50-Day Moving Average | 16.30 |
| 200-Day Moving Average | 16.14 |
| Relative Strength Index (RSI) | 35.10 |
| Average Volume (20 Days) | 5,449,495 |
Short Selling Information
The latest short interest is 42.26 million, so 26.67% of the outstanding shares have been sold short.
| Short Interest | 42.26M |
| Short Previous Month | 40.90M |
| Short % of Shares Out | 26.67% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.56 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -855.24M |
| Pretax Income | -832.68M |
| Net Income | -832.68M |
| EBITDA | -855.03M |
| EBIT | -855.24M |
| Earnings Per Share (EPS) | -$1.07 |
Balance Sheet
The company has $629.79 million in cash and $19.98 million in debt, with a net cash position of $609.81 million or $0.76 per share.
| Cash & Cash Equivalents | 629.79M |
| Total Debt | 19.98M |
| Net Cash | 609.81M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 564.68M |
| Book Value Per Share | 0.71 |
| Working Capital | 550.50M |
Cash Flow
In the last 12 months, operating cash flow was -$525.17 million and capital expenditures -$1.71 million, giving a free cash flow of -$526.88 million.
| Operating Cash Flow | -525.17M |
| Capital Expenditures | -1.71M |
| Depreciation & Amortization | 217,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -526.88M |
| FCF Per Share | -$0.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SMMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.30% |
| Shareholder Yield | -5.30% |
| Earnings Yield | -9.23% |
| FCF Yield | -5.60% |
Analyst Forecast
The average price target for SMMT is $29.37, which is 153.85% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.37 |
| Price Target Difference | 153.85% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |